William Blair Investment Management LLC lowered its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 3.4% in the 3rd quarter, Holdings Channel reports. The fund owned 31,087 shares of the pharmaceutical company’s stock after selling 1,085 shares during the period. William Blair Investment Management LLC’s holdings in Vertex Pharmaceuticals were worth $16,253,000 as of its most recent filing with the SEC.
A number of other large investors have also modified their holdings of VRTX. Guidance Capital Inc. grew its position in Vertex Pharmaceuticals by 0.9% in the 3rd quarter. Guidance Capital Inc. now owns 2,230 shares of the pharmaceutical company’s stock worth $1,234,000 after purchasing an additional 19 shares during the last quarter. Bangor Savings Bank raised its holdings in shares of Vertex Pharmaceuticals by 0.4% during the second quarter. Bangor Savings Bank now owns 4,470 shares of the pharmaceutical company’s stock valued at $2,220,000 after buying an additional 20 shares during the last quarter. Trust Point Inc. raised its holdings in shares of Vertex Pharmaceuticals by 2.7% during the second quarter. Trust Point Inc. now owns 793 shares of the pharmaceutical company’s stock valued at $394,000 after buying an additional 21 shares during the last quarter. Integrated Advisors Network LLC boosted its position in shares of Vertex Pharmaceuticals by 1.4% during the third quarter. Integrated Advisors Network LLC now owns 1,625 shares of the pharmaceutical company’s stock worth $850,000 after buying an additional 22 shares during the period. Finally, Glenview Trust Co boosted its position in shares of Vertex Pharmaceuticals by 0.3% during the third quarter. Glenview Trust Co now owns 6,773 shares of the pharmaceutical company’s stock worth $3,541,000 after buying an additional 22 shares during the period. Institutional investors and hedge funds own 90.96% of the company’s stock.
Wall Street Analyst Weigh In
Several research firms recently commented on VRTX. TD Cowen raised their target price on Vertex Pharmaceuticals from $550.00 to $575.00 and gave the company a “buy” rating in a research report on Tuesday, November 3rd. Truist Financial lifted their target price on Vertex Pharmaceuticals from $560.00 to $565.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Leerink Partners initiated coverage on Vertex Pharmaceuticals in a research report on Monday, September 21st. They set an “outperform” rating and a $594.00 price target for the company. Evercore lifted their price objective on shares of Vertex Pharmaceuticals from $535.00 to $600.00 and gave the company an “outperform” rating in a research note on Wednesday, September 2nd. Finally, Canaccord Genuity Group upped their price objective on shares of Vertex Pharmaceuticals from $436.00 to $442.00 and gave the stock a “hold” rating in a report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $596.44.
Vertex Pharmaceuticals Price Performance
Shares of NASDAQ:VRTX opened at $538.60 on Monday. Vertex Pharmaceuticals Incorporated has a one year low of $412.27 and a one year high of $568.67. The stock has a fifty day moving average of $522.37 and a 200-day moving average of $483.84. The company has a market capitalization of $136.56 billion, a PE ratio of 34.66, a price-to-earnings-growth ratio of 2.85 and a beta of 0.28. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.89 and a current ratio of 2.34.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last issued its earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06). The company had revenue of $3.44 billion during the quarter, compared to analyst estimates of $3.42 billion. Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. The business’s revenue was up 11.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $4.80 earnings per share. As a group, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 16.10 EPS for the current fiscal year.
Vertex Pharmaceuticals Profile
Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.
Read More
- Five stocks we like better than Vertex Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
